Search

Your search keyword '"Kalidas, Kavita"' showing total 26 results
Start Over Author "Kalidas, Kavita"
26 results on '"Kalidas, Kavita"'

1. Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data

Author

Kudrow, David, primary, Dafer, Rima, additional, Dodick, David W., additional, Starling, Amaal, additional, Ailani, Jessica, additional, Dougherty, Carrie, additional, Kalidas, Kavita, additional, Zhang, Feng, additional, Jeswani, Rohini, additional, Patel, Nishil, additional, and Khodavirdi, Ani C., additional

Published
2023
Full Text
View/download PDF

2. Migraines in women: fluctuating hormones play a role in migraines, making it important to consider hormonal milestones and factors when formulating a treatment plan

Author

Kalidas, Kavita

Subjects
Postmenopausal women -- Physiological aspects -- Research, Migraine -- Risk factors -- Demographic aspects -- Research, Hormone therapy -- Complications and side effects -- Research, Health
Abstract

Headache is among the most common neurological conditions with a current worldwide prevalence in the general population of 47%. (1) The Global Burden of Disease Study 2015 ranks headache disorders [...]

Published
2017

3. Medical marijuana in neurology

Author

Benbadis, Selim R, Sanchez-Ramos, Juan, Bozorg, Ali, Giarratano, Melissa, Kalidas, Kavita, Katzin, Lara, Robertson, Derrick, Vu, Tuan, Smith, Amanda, and Zesiewicz, Theresa

Published
2014
Full Text
View/download PDF

6. sj-pdf-3-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-3-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

7. sj-pdf-10-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-10-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

8. sj-pdf-5-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-5-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

9. sj-pdf-9-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-9-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

10. sj-pdf-6-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-6-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

11. sj-pdf-4-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-4-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

12. sj-pdf-2-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-2-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

13. sj-pdf-8-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-8-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

14. sj-pdf-1-cep-10.1177_0333102420920642 - Supplemental material for Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine

Author

Martinez, James M, Hindiyeh, Nada, Anglin, Greg, Kalidas, Kavita, Hodsdon, Michael E, Kielbasa, William, Moser, Brian A, Pearlman, Eric M, and Garces, Sandra

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-1-cep-10.1177_0333102420920642 for Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine by James M Martinez, Nada Hindiyeh, Greg Anglin, Kavita Kalidas, Michael E Hodsdon, William Kielbasa, Brian A Moser, Eric M Pearlman and Sandra Garces in Cephalalgia

Published
2020
Full Text
View/download PDF

15. sj-pdf-7-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, Adams, Aubrey M, Abhijeet Jakate, Chengcheng Liu, Szegedi, Armin, and Trugman, Joel M

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-7-cep-10.1177_0333102420970523 for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications by Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi and Joel M Trugman in Cephalalgia

Published
2020
Full Text
View/download PDF

18. Contributors

Author

Baumgras, Anna, primary, Beasley-Greenwood, Maureen, additional, Beran, Roy G., additional, Cooney, Mark, additional, Crosley, Adair, additional, Gold, Mark S., additional, Goldberger, Bruce A., additional, Greenwood, Mark J., additional, Greer, Richard A., additional, Hammer, Peter J., additional, Kalidas, Kavita, additional, Kim, Susan C., additional, Kremling, Janine, additional, Levy, Woodburne O., additional, Loue, Sana, additional, Merves, Michele L., additional, Miller, Norman S., additional, Peters, Roger H., additional, Ray, John M., additional, Silberberg, Joel M., additional, Spitz, Werner U., additional, Spratt, Sara, additional, Stone, Lesley, additional, and Vandervort, Frank E., additional

Published
2010
Full Text
View/download PDF

26. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.

Author

Goadsby, Peter J, Blumenfeld, Andrew M, Lipton, Richard B, Dodick, David W, Kalidas, Kavita, M Adams, Aubrey, Jakate, Abhijeet, Liu, Chengcheng, Szegedi, Armin, and Trugman, Joel M

Subjects
*MIGRAINE, *ANALGESIA, *CALCITONIN gene-related peptide
Abstract

Background: The full utility of an acute treatment requires examination of the entire time course of effect during a migraine attack. Here the time course of effect of ubrogepant is evaluated. Methods: ACHIEVE-I and -II were double-blind, single-attack, Phase 3 trials. Adults with migraine were randomised 1:1:1 to placebo or ubrogepant (50mg or 100mg, ACHIEVE-I; 25 mg or 50 mg, ACHIEVE-II). Pain freedom, absence of most bothersome symptom, and pain relief were assessed at various timepoints. Samples were collected for pharmacokinetic analysis. Data were pooled for this post-hoc analysis. Results: Participants' (n = 912 placebo, n = 887 ubrogepant 50 mg, pooled analysis population) mean age was 41 years, with a majority female and white. Pain relief separated from placebo by 1 h (43% versus 37% [OR, 95% CI: 1.30, 1.0–1.59]), absence of most bothersome symptom by 1.5 h (28% versus 22% [1.42, 1.14–1.77]), and pain freedom by 2 h (20% vs. 13% [1.72, 1.33–2.22]). Efficacy was sustained from 2–24 h (pain relief: 1.71, 1.1–2.6; pain freedom: 1.71, 1.3–2.3) and remained separated at 48 h (pain relief: 1.7, 1.1–2.6; pain freedom: 1.31, 1.0–1.7). Pharmacokinetic analysis demonstrated maximum plasma concentrations were achieved at 1 h, with pharmacologically active concentrations reached within 11 min and remaining above the EC90 for nearly 12 h. Conclusions: Evaluation of the time course of effect of ubrogepant showed pain relief as the most sensitive and earliest measure of clinical effect, followed by absence of most bothersome symptom, and pain freedom. Efficacy was demonstrated out to 48 h, providing evidence of the long-lasting effect of ubrogepant. This evaluation supports the role of examining the entire time course of effect to understand fully the utility of an acute treatment for migraine. Trial registration: ACHIEVE I (ClinicalTrials.gov, NCT02828020) and ACHIEVE II (ClinicalTrials.gov, NCT02867709) [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results